Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial
Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial
Regeneron和賽諾菲安萬特的Dupixent成爲首個在大皰性天皰瘡試驗中取得顯著療效改善的生物製劑。
- Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
- Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease
- If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union
- 該試驗符合成人中度至重度疾病的主要和所有關鍵次要終點；使用Dupixent實現持續緩解的患者是安慰劑的五倍
- Dupixent是第一種對這種使人衰弱和危及生命的疾病顯示出顯著的類固醇保護作用的藥物
- 如果獲得批准，Dupixent將成爲美國和歐盟第一種也是唯一一種治療血壓的靶向藥物